Clinical Development - The company completed the development of the frozen formulation of Allocetra™ twelve months ahead of schedule, which is expected to have a shelf life spanning multiple years, improving scalability and reducing production costs [19]. - The Phase II trial for sepsis is integrating the frozen formulation of Allocetra™, expanding the study population to include patients with higher SOFA scores, with top-line data readouts expected in Q1 2024 [20][21]. - The company initiated a Phase I/II trial for Allocetra™ in combination with chemotherapy for patients with peritoneal metastases, with data readouts expected by Q2 2024 [23]. - A second Phase I/II trial is evaluating Allocetra™ combined with anti-PD-1 checkpoint inhibitors, with enrollment completion expected by the end of Q2 2023 [24]. - The company received positive recommendations from the Data and Safety Monitoring Board to continue its clinical trials, indicating progress in its research efforts [23][24]. Financial Performance and Projections - The company has not generated any revenue from Allocetra™ or any other product candidate, and it may never be profitable [32]. - The company expects to incur additional losses in the future and will need substantial additional capital to continue operations [32]. - The company has incurred losses of $31 million and $14.4 million for the years ended December 31, 2022, and 2021, respectively, with an accumulated deficit of approximately $83 million as of December 31, 2022 [41]. - The company expects research and development expenses to increase due to planned pre-clinical studies and clinical trials, leading to continued significant operating losses [42]. - The company anticipates needing substantial additional capital to fund operations and develop product candidates, particularly Allocetra™, with a potential cash runway extending into 2025 [50]. - The company has no current source of revenue and does not expect to generate revenue until regulatory approval and successful commercialization of its product candidates [56]. Regulatory and Compliance Challenges - The company has not received regulatory clearance to conduct necessary clinical trials for Allocetra™ in the U.S. or other countries [60]. - The clinical trial process is expensive and subject to delays due to various factors, including regulatory requirements and patient recruitment challenges [67]. - Even if clinical trials are successful, obtaining regulatory approval is lengthy and uncertain, with potential for delays or denials [69]. - Approval in one jurisdiction does not guarantee approval in others, which may impair the ability to develop foreign markets for Allocetra™ [62]. - Changes in regulatory requirements during clinical trials may increase costs and delay timelines [73]. - Non-compliance with regulatory requirements could lead to sanctions, including fines, product recalls, and operational restrictions [80]. Manufacturing and Operational Risks - The company completed construction of its cGMP Allocetra™ manufacturing plant on schedule, but the move into the new facility has been deferred for approximately three years as part of a cost-cutting program [26]. - Manufacturing processes are complex and susceptible to contamination, which could impact the availability of raw materials and finished products [74]. - The company faces risks of write-offs and costs due to the complex nature of blood and potential contamination of product candidates [77]. - Regulatory compliance is critical, as failure to meet manufacturing regulations could adversely affect financial results and operations [78]. - The company may incur additional costs and face integration difficulties if it acquires or in-licenses new technologies or product candidates [100]. Market and Competitive Landscape - The company faces intense competition from larger pharmaceutical and biotechnology companies, which may have more resources and experience [112]. - Market acceptance of Allocetra™ will depend on factors such as clinical safety, efficacy, and the willingness of patients to pay out of pocket [97]. - The company may face significant regulatory hurdles even after receiving marketing approval, which could impact commercialization [92]. - Obtaining coverage and reimbursement approval from third-party payors is a time-consuming and costly process that may impact the commercialization of future products [108]. Intellectual Property Risks - The company faces risks related to intellectual property, including the uncertainty of obtaining and maintaining patents [149]. - There is no guarantee that pending patent applications will result in issued patents, which could significantly affect the company's competitive advantage [150]. - The company may face litigation related to intellectual property rights, which can be costly and time-consuming [167]. - There is a risk that third parties may claim infringement of their patents, potentially halting the company's operations [168]. Shareholder and Market Considerations - Approximately 19.47% of the company's outstanding ordinary shares are owned by principal shareholders, directors, and officers, allowing them to exert significant influence over shareholder decisions [178]. - The company does not intend to declare cash dividends in the foreseeable future, meaning shareholders must rely on capital appreciation for returns on their investment [182]. - The trading price of the company's ordinary shares is likely to be volatile, influenced by factors such as clinical trial results and regulatory approvals [175]. Geographic and Political Risks - The company operates in Israel, where political and military instability could adversely affect its business operations and financial results [186]. - The company's ordinary shares are traded on both the Nasdaq Capital Market and the Tel Aviv Stock Exchange, which may lead to price variations due to different currencies and trading times [185]. - The company’s operations may be adversely affected by Israeli government policies and military service obligations, which could disrupt business continuity [191].

Financial Performance - The net loss for 2022 was $31,060,000, compared to a net loss of $14,468,000 in 2021, indicating an increase in losses of approximately 114.5%[17]. - Basic and diluted loss per share increased to $1.69 in 2022, compared to $0.81 in 2021, representing a rise of approximately 108.6%[17]. - Total comprehensive loss for 2022 was $31,060,000, compared to a total comprehensive loss of $14,344,000 in 2021, an increase of approximately 116.5%[17]. - For the year ended December 31, 2022, Enlivex Therapeutics Ltd. reported a net loss of $31.06 million, an increase of 114% compared to a net loss of $14.47 million in 2021[21]. - The company incurred net cash used in operating activities of $23.95 million in 2022, compared to $17.54 million in 2021, reflecting a 36.6% increase[21]. Assets and Equity - Total assets decreased to $67,642,000 as of December 31, 2022, down from $95,146,000 in 2021, representing a decline of approximately 29.1%[16]. - Total shareholders' equity decreased to $56,841,000 in 2022 from $85,039,000 in 2021, a decline of approximately 33.3%[16]. - Enlivex's accumulated deficit reached $83.2 million as of December 31, 2022, indicating ongoing financial challenges since the company has not generated any revenues or product sales[27]. - As of December 31, 2022, the company had total financial assets of $50,656 thousand, a decrease from $84,564 thousand in 2021[134]. Cash and Cash Equivalents - Cash and cash equivalents increased significantly to $49,945,000 in 2022, compared to $11,202,000 in 2021, marking an increase of approximately 345.5%[16]. - Cash, cash equivalents, and restricted cash at the end of 2022 totaled $50.36 million, a significant increase from $11.64 million at the end of 2021[21]. - Total cash and cash equivalents increased to $49,945 thousand in 2022 from $11,202 thousand in 2021, representing a growth of 345%[80]. - Total cash, cash equivalents, and restricted cash shown in the statement of cash flows reached $50,357 thousand in 2022, up from $11,636 thousand in 2021, marking a 332% increase[80]. Research and Development - Research and development expenses rose to $18,693,000 in 2022, up from $12,881,000 in 2021, reflecting a growth of approximately 45.3%[17]. - Research and development expenses for the year ended December 31, 2022, totaled $19,900 thousand, an increase from $13,901 thousand in 2021[135]. - Enlivex's research and development activities are expected to require additional cash investment for preclinical studies and clinical trials, necessitating further financing[28]. - Research and development expenses include costs directly attributable to R&D programs, with all costs expensed as incurred[54]. Operating Expenses - Operating expenses totaled $25,797,000 in 2022, up from $19,288,000 in 2021, which is an increase of approximately 33.9%[17]. - General and administrative expenses for the year ended December 31, 2022, amounted to $7,104 thousand, compared to $6,407 thousand in 2021[136]. - Operating lease expenses for 2022 amounted to $1,037 thousand, up from $698 thousand in 2021, representing a 49% increase[96]. Financing and Capital Structure - The company plans to finance its operations through equity securities issuances and anticipates continuing to incur losses for several years[28]. - The Company entered into an ATM Agreement on December 30, 2022, allowing for the sale of Ordinary Shares with an aggregate offering price of up to $100 million[109]. - The Company sold 476,983 Ordinary Shares under the Former ATM Agreement, resulting in a gross aggregate offering price of $8,557 thousand at an average price of $17.94 per share[108]. - The net proceeds from the February 2021 Offering were $47,023 thousand after deducting fees and expenses[108]. Shareholder Information - The number of shares outstanding increased to 18,421,852 as of December 31, 2022, from 18,331,507 in 2021, reflecting a growth of approximately 0.5%[19]. - As of December 31, 2022, the Company had 202,251 warrants outstanding with a weighted average exercise price of $23.31[114]. - The total unrecognized estimated compensation cost related to non-vested stock options was $2,746 thousand, expected to be recognized over a weighted average period of 1.61 years[119]. - The Company granted 860,492 stock options in 2022 at a weighted average exercise price of $5.49[118]. Tax and Regulatory Matters - The Company has not paid income taxes since its incorporation, with a statutory tax rate of 23%[126]. - As of December 31, 2022, the Company recorded a liability of $705 thousand for uncertain tax positions[61]. Other Financial Metrics - The company reported interest income of $835 thousand for the year ended December 31, 2022, significantly up from $120 thousand in 2021[137]. - The Company recorded charges related to patent costs of approximately $536 thousand, $373 thousand, and $374 thousand for the years ended December 31, 2022, 2021, and 2020, respectively[58]. - The intrinsic value of options exercised during 2022 was $0[120]. - The weighted average risk-free interest rate for stock options was 3.41% in 2022[117].

Financial Performance - The net loss for the nine months ended September 30, 2022, was $23,871 thousand, compared to a net loss of $9,732 thousand for the same period in 2021, representing a 145% increase in losses[14]. - Basic and diluted loss per share for the three months ended September 30, 2022, was $0.31, compared to $0.19 for the same period in 2021, indicating a 63% increase in loss per share[14]. - The company expects to continue incurring losses for at least the next several years, necessitating further financing or partnerships[35]. Assets and Liabilities - Total assets decreased from $95,146 thousand as of December 31, 2021, to $72,414 thousand as of September 30, 2022, representing a decline of approximately 24%[8]. - Total shareholders' equity decreased from $85,039 thousand as of December 31, 2021, to $63,274 thousand as of September 30, 2022, a decline of approximately 26%[11]. - Total liabilities decreased from $10,107 thousand as of December 31, 2021, to $9,140 thousand as of September 30, 2022, a reduction of approximately 10%[11]. Cash and Cash Equivalents - Cash and cash equivalents increased significantly from $11,202 thousand in December 2021 to $57,655 thousand in September 2022, indicating a growth of over 414%[8]. - The company reported an increase in cash and cash equivalents of $46,415 thousand for the nine months ended September 30, 2022[25]. - As of September 30, 2022, total cash and cash equivalents amounted to $57.655 million, a significant increase from $11.202 million as of December 31, 2021[56]. Research and Development - Research and development expenses for the three months ended September 30, 2022, were $4,201 thousand, up from $2,679 thousand for the same period in 2021, reflecting a 57% increase[14]. - The Company submitted a grant application for $4.8 million for its clinical development program related to sepsis, receiving approximately $960 thousand for its ongoing Phase II trial[70]. - The company is focused on developing Allocetra, a macrophage reprogramming immunotherapy, which is critical for immune system rebalancing[31]. Share-Based Compensation - The company incurred share-based compensation expenses of $1,955 thousand for the nine months ended September 30, 2022, up from $1,219 thousand in the prior year[25]. - Total share-based compensation expenses for the three months ended September 30, 2022, were $471,000, compared to $377,000 for the same period in 2021, representing an increase of 24.9%[83]. - For the nine months ended September 30, 2022, total share-based compensation expenses were $1,955,000, up from $1,219,000 in the same period of 2021, reflecting a growth of 60.5%[83]. Other Financial Information - The company reported other income/(expense), net of $(56) thousand for the three months ended September 30, 2022, compared to $440 thousand for the same period in 2021, indicating a significant decline in other income[14]. - The accumulated deficit as of September 30, 2022, reached $75,836 thousand, indicating ongoing financial challenges[34]. - The company has not generated any revenues or product sales and has not achieved profitable operations since its inception[34]. Marketable Securities and Financial Assets - Marketable securities were valued at $62,924,000, indicating a stable asset position[86]. - As of September 30, 2022, total financial assets amounted to $58,051,000, consistent with the same amount as of December 31, 2021[86]. - The company held restricted cash of $283,000 as of September 30, 2022, unchanged from the previous period[86]. Operational and Other Expenses - General and administrative expenses rose from $1,185 thousand in Q3 2021 to $1,476 thousand in Q3 2022, marking a 25% increase[14]. - Depreciation expenses for the nine month period ended September 30, 2022 were $556 thousand, compared to $396 thousand for the same period in 2021[59]. - Laboratory equipment costs increased to $2.679 million as of September 30, 2022, from $1.891 million as of December 31, 2021[59]. Equity and Warrants - As of September 30, 2022, there were 202,251 outstanding warrants with a weighted average exercise price of $23.31[72]. - The total number of options outstanding at the end of the period was 2,377,622, with a weighted average exercise price of $5.95[75]. - The Company had 1,787,448 exercisable options at the end of the period, with a weighted average exercise price of $5.14[79].

Financial Performance - The company reported a net loss of $8.225 million for the three months ended March 31, 2022, compared to a net loss of $3.200 million for the same period in 2021, indicating an increase in losses of approximately 157.3%[11] - Basic and diluted loss per share for the first quarter of 2022 was $0.45, compared to $0.19 for the same period in 2021, indicating a worsening of approximately 136.8%[11] - The company reported total operating expenses of $6.404 million for the first quarter of 2022, compared to $3.802 million for the same period in 2021, representing an increase of approximately 68.5%[11] - The company reported a net loss of $8,225 thousand for March 2022, compared to a net loss of $3,200 thousand for March 2021, indicating a significant increase in losses[19] - The accumulated deficit as of March 31, 2022, reached $60,190 thousand, reflecting ongoing financial challenges since inception[28] Assets and Liabilities - As of March 31, 2022, total assets decreased to $88.621 million from $95.146 million as of December 31, 2021, representing a decline of approximately 6.4%[8] - Total current liabilities increased to $5.743 million as of March 31, 2022, compared to $4.718 million as of December 31, 2021, marking an increase of approximately 21.7%[8] - The company's accumulated deficit grew to $60.190 million as of March 31, 2022, compared to $51.965 million at the end of 2021, representing an increase of approximately 15.8%[8] - The total shareholders' equity decreased to $77.652 million as of March 31, 2022, down from $85.039 million at the end of 2021, reflecting a decline of approximately 8.6%[8] - The total financial assets as of March 31, 2022, amount to $78,427 thousand, compared to $84,564 thousand as of December 31, 2021[77] Cash Flow and Investments - Cash and cash equivalents increased significantly to $67.666 million as of March 31, 2022, from $11.202 million as of December 31, 2021, showing a growth of approximately 504.5%[8] - Cash flows from operating activities showed a net cash used of $3,269 thousand for March 2022, compared to $2,340 thousand for March 2021, highlighting increased operational cash burn[19] - The company generated net cash provided by investing activities of $59,674 thousand in March 2022, a significant recovery from a net cash used of $59,589 thousand in March 2021[19] - Cash and cash equivalents at the end of the period were $68,091 thousand, a substantial increase from $5,400 thousand at the end of March 2021[19] - Total cash and cash equivalents increased to $67,666 thousand as of March 31, 2022, compared to $11,202 thousand on December 31, 2021, representing a growth of 503%[50] Research and Development - Research and development expenses for the first quarter of 2022 were $4.682 million, up from $2.497 million in the same quarter of 2021, reflecting an increase of approximately 87.5%[11] - The company has incurred significant capital investments in research and development, with expectations for continued cash investment in clinical trials and related activities[28] - The company has not generated any revenues or product sales and continues to rely on raising capital to support research and development activities[28] - The company expects to incur losses for at least the next several years and will need to secure additional financing to fund its development[29] Shareholder Information - The weighted average number of shares outstanding increased to 18,369,827 for the first quarter of 2022, compared to 16,479,750 for the same period in 2021, indicating an increase of approximately 11.5%[11] - The company has a total of 4,150,704 Ordinary Shares authorized for issuance under the 2019 Equity Incentive Plan, with 1,186,343 shares available for future grant[67] - The total number of options outstanding is 2,399,622, with an intrinsic value of $2,475,465 thousand[73] - The number of options exercisable as of March 31, 2022, is 1,676,873[73] - The company recognized share-based compensation expense of $788 thousand for the three months ended March 31, 2022, compared to $190 thousand for the same period in 2021[76] Grants and Funding - The gross amount of grants received from the Israeli Innovation Authority was approximately $8 million as of March 31, 2022, with no royalties paid yet[62] - The company submitted a grant application for $4.8 million for its clinical development program, expecting to receive up to $1 million if approved[63] - The company received approval for a 2022 Sepsis Grant Application amounting to NIS 4.0 million (approximately $1.2 million) in May 2022[80] Other Financial Metrics - Property and equipment net value increased to $3,294 thousand as of March 31, 2022, up from $2,530 thousand, marking a 30.2% rise[53] - Accrued expenses and other liabilities totaled $4,272 thousand, an increase of 14.6% from $3,727 thousand as of December 31, 2021[55] - Share-based compensation expenses for the three months ended March 31, 2022, were $565 thousand, compared to $175 thousand for the same period in 2021, indicating a 222.9% increase[72] - The fair value of restricted stock units not yet recognized as of March 31, 2022, is $1,077 thousand, expected to be recognized over a weighted average period of 1.75 years[75] - The total number of shares granted during the period was 48,375, with a grant fair value of $14.67[75]

Product Development and Trials - Enlivex completed the development of the frozen formulation of Allocetra™ twelve months ahead of schedule, which is expected to have a shelf life spanning multiple years, improving scalability and production costs [21]. - The Phase II sepsis trial will now utilize the frozen formulation of Allocetra™, with protocol amendments expected to be submitted to regulators in Q2 2022, potentially deferring trial completion by 6-8 months [23]. - The Phase Ib trial of Allocetra™ demonstrated a favorable safety profile and improved clinical outcomes, with over 1.7 million adults in the U.S. developing sepsis annually, leading to more than 270,000 deaths [24]. - Enlivex plans to initiate a Phase Ib trial for Allocetra™ in combination with chemotherapy for solid peritoneal tumors in Q3 2022, and a Phase I/II trial with an immune checkpoint inhibitor in late 2022 [27]. - The company is de-prioritizing Allocetra's clinical development for COVID-19 due to regulatory challenges and resource reallocation towards sepsis and oncology [25]. Financial Performance and Projections - Enlivex has not generated any revenue from Allocetra™ or other product candidates and anticipates incurring additional losses in the future [37]. - The company has incurred losses of $14.4 million and $11.8 million for the years ended December 31, 2021, and 2020, respectively, with an accumulated deficit of approximately $51.9 million as of December 31, 2021 [48]. - The company expects research and development expenses to increase due to planned pre-clinical studies, clinical trials, and the construction of a new manufacturing facility [49]. - The company anticipates significant additional capital will be required to fund operations and develop product candidates, particularly Allocetra™ [60]. - The company has sustained operating losses and expects these losses to continue for the foreseeable future, with a substantial doubt about continuing operations beyond Q3 2024 without additional financing [69]. Regulatory and Market Challenges - The company is subject to extensive regulatory requirements and potential future development difficulties even if Allocetra™ receives marketing approval [48]. - The company has not received regulatory clearance to conduct necessary clinical trials for filing a Biologics License Application (BLA) with the FDA, which could delay commercialization efforts [75]. - Regulatory approval processes are lengthy and uncertain, with various factors that could delay or deny approval for product candidates [90]. - Even if regulatory approval is obtained, it may come with significant limitations that could hinder the commercialization of Allocetra™ or other product candidates [93]. - The company faces risks related to the acceptance and reimbursement of its products by government agencies and third-party payors, which could affect commercial viability [79]. Manufacturing and Operational Risks - Construction of the new cGMP Allocetra™ manufacturing plant in Israel is on schedule, with an initial size of approximately 17,000 square feet, expandable to 21,500 square feet, expected to be completed in Q4 2022 [28]. - The manufacturing process for Allocetra™ is complex and must adhere to stringent cGMP requirements, with any non-compliance potentially resulting in product destruction or recalls [100]. - The company must ensure the safety of its blood supply against transmissible diseases, as risks remain despite existing safeguards, which could impair product manufacturing and distribution [109]. - The company has invested almost all its resources in Allocetra™, indicating a high dependency on the success of this single product candidate [74]. - The company faces potential write-offs and costs due to the complex nature of blood and its processes, which could lead to material fluctuations in liquidity and operational results [101]. Competition and Market Dynamics - The company faces intense competition from larger pharmaceutical and biotechnology companies, which may have more resources and experience in drug development and commercialization [145]. - Sales in Europe and other countries will depend on the availability of reimbursement from third-party payors, who are increasingly challenging pricing and cost-effectiveness [133]. - The company anticipates that government authorities and third-party payors will impose strict requirements for reimbursement, which may limit off-label use of higher-priced drugs [137]. - Obtaining coverage and reimbursement approval is a time-consuming and costly process, and the company cannot guarantee that adequate reimbursement will be available for future products [138]. Intellectual Property and Legal Risks - The company faces risks related to the failure to obtain or maintain patents, which could impact its competitive position [191]. - The company may infringe on the intellectual property rights of others, which could delay product development and increase commercialization costs [210]. - The company’s success is heavily dependent on intellectual property, particularly patents, which are costly and time-consuming to obtain and enforce [206]. - The company may not be able to enforce its intellectual property rights globally, particularly in developing countries where patent laws are less favorable [201]. - The company may be subject to significant costs and litigation to defend intellectual property rights licensed from third parties [208]. Management and Operational Structure - The company relies heavily on its ability to attract and retain qualified senior executive officers, with a particular emphasis on scientific and technical experience, which is critical for its business operations [160]. - The company has incurred significant costs due to its status as a public company, including legal and accounting expenses, which may hinder its ability to comply with regulatory requirements [162][163]. - The company faces intense competition for qualified personnel in the pharmaceutical field, which may affect its ability to recruit and retain necessary staff [160]. - The company does not currently carry "key person" insurance for its senior management, which could pose risks if key personnel are lost [160]. Economic and Geopolitical Factors - The company is operating in a period of economic uncertainty and capital markets disruption, significantly impacted by geopolitical instability [37]. - The ongoing military conflict between Russia and Ukraine has created economic uncertainty and capital market disruptions, which may materially adversely affect the company's business and financial condition [71]. - The COVID-19 pandemic has caused delays in the development of clinical programs and manufacturing of Allocetra™, impacting the company's operations and financial condition [186][187].

Product Development - Enlivex completed the development of the frozen formulation Allocetra™ twelve months ahead of schedule in Q1 2022, significantly improving shelf-life and scalability[2] - The frozen formulation is expected to lower production costs and increase profitability upon potential commercialization, with a shelf life spanning multiple years compared to the liquid formulation's 96 hours[3] - Enlivex plans to integrate the frozen formulation into its ongoing Phase II sepsis trial, which may defer trial completion by approximately six to eight months but shorten the overall timeline for regulatory approval[4] - Enlivex plans to initiate two clinical trials for Allocetra™ in solid tumor patients in 2022, including a Phase Ib trial in Q3 2022 and a Phase I/II trial in late 2022[8] Clinical Trials - The company is de-prioritizing Allocetra's clinical development in COVID-19 due to emerging variants and a more stringent regulatory environment, reallocating resources to sepsis and oncology[6] - Enlivex's Phase IIb COVID-19 trial has seen slow recruitment, with only 11 patients enrolled, leading to the decision to cease recruitment[7] Financial Performance - The company's cash runway is expected to extend to Q3 2024 due to the re-prioritization of resources, with cash and marketable securities totaling $84.1 million as of December 31, 2021[11][14] - Research and development expenses for 2021 were $12.8 million, up from $6.0 million in 2020, while general and administrative expenses increased to $6.4 million from $3.7 million[13] - The net loss for 2021 was $14.4 million, compared to a net loss of $11.8 million in 2020[13] Manufacturing - The construction of Enlivex's new cGMP manufacturing plant in Israel is on schedule, with an initial size of approximately 17,000 square feet and potential expansion to 21,500 square feet[9]

Financial Performance - Operating loss for the three months ended September 30, 2021, was $3,864,000, compared to $1,959,000 for the same period in 2020, indicating an increase in losses of 97.1%[10] - Net loss for the nine months ended September 30, 2021, was $9,732,000, compared to $5,960,000 in 2020, an increase of 63.2%[10] - Total comprehensive loss for the nine months ended September 30, 2021, was $(9,608,000), compared to $(5,861,000) for the same period in 2020, an increase of 63.5%[10] - The company reported a net loss of $9,732 thousand for the nine months ended September 30, 2021, compared to a net loss of $5,960 thousand for the same period in 2020, indicating an increase in losses[21] - The company expects to continue incurring losses for at least the next several years and will need to raise additional financing to support its development activities[31] Assets and Liabilities - Total current assets increased to $90,281,000 as of September 30, 2021, compared to $38,121,000 as of December 31, 2020, representing an increase of 136.5%[7] - Total liabilities increased to $10,084,000 as of September 30, 2021, from $4,871,000 as of December 31, 2020, a rise of 106.5%[7] - Shareholders' equity grew to $88,083,000 as of September 30, 2021, compared to $35,487,000 as of December 31, 2020, an increase of 148.5%[7] - Cash and cash equivalents rose to $22,146,000 from $5,673,000, a growth of 289.5%[7] - Cash and cash equivalents at the end of the period were $23,327 thousand, up from $6,397 thousand at the beginning of the period, showing a significant increase in liquidity[21] Research and Development - Research and development expenses for the nine months ended September 30, 2021, totaled $7,715,000, up from $3,642,000 in 2020, reflecting a 112.8% increase[10] - The company is developing Allocetra, a universal cell therapy aimed at reprogramming macrophages, which is critical for treating conditions like solid tumors and COVID-19[25] - The Phase IIb clinical trial for Allocetra in patients with severe sepsis is expected to yield interim results in the first or second quarter of 2022, with top-line results anticipated in the fourth quarter of 2022[35] Financing Activities - The company issued shares and warrants for cash consideration of $57,629,000 net of issuance costs during the reporting period[13] - The company raised a net amount of $53.2 million from the issuance of 2,848,629 ordinary shares and an additional $7.7 million from the exercise of warrants and options during the first quarter of 2021[31] - The company plans to finance its operations through equity securities issuances and expects to require additional capital to support its long-term development[34] Stock Options and Compensation - As of September 30, 2021, the total unrecognized estimated compensation cost related to outstanding nonvested stock options was $2,822 thousand, expected to be recognized over a weighted average period of 3.96 years[90] - The Company authorized an increase of 1,800,000 ordinary shares for issuance to employees, directors, and consultants, totaling 4,150,704 shares authorized under the 2019 Equity Incentive Plan[86] - The Company recognized share-based compensation expenses of $336 thousand and $1,114 thousand for the three and nine months ended September 30, 2021, respectively[90] Grants and Other Income - The Company received approximately $8 million in grants from the Israeli Innovation Authority (IIA) as of September 30, 2021, with no royalties paid to the IIA yet[66] - The Company was approved for a new grant from the IIA amounting to NIS 3.8 million ($1.16 million) for its clinical development program related to sepsis[67] Miscellaneous - The company has not generated any revenues or product sales and has not achieved profitable operations or positive cash flow from operations[30] - The company does not expect any material impact on its liquidity due to the COVID-19 pandemic, although clinical trial timelines may be extended[35]

United States Securities and Exchange Commission Washington, D.C. 20549 Title of each class Trading symbol Name of each exchange on which registered Ordinary Shares, par value of NIS 0.40 ENLV Nasdaq Capital Market FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Commission file number 001-36578 Enlivex Therapeutics Ltd. (Exact name of Registrant as specified in its charter) State of Israel (Jurisdiction of incorporati ...

Ticker: ENLV | --- | --- | --- | |--------------|---------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Life-saving | | | | October 2020 | immunomodulating cell therapies | | Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activ ...

United States Securities and Exchange Commission Washington, D.C. 20549 Title of each class Trading symbol Name of each exchange on which registered Ordinary Shares, par value of NIS 0.40 ENLV Nasdaq Capital Market FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Commission file number 001-36578 Enlivex Therapeutics Ltd. (Exact name of Registrant as specified in its charter) State of Israel (Jurisdiction of incorporati ...